A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics
Status:
Recruiting
Trial end date:
2022-05-07
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy and safety of IND068 once daily (QD) in
subjects with type 2 diabetes not adequately controlled with one or two oral antidiabetics
compared to insulin degludec QD for 16 weeks.